在霍奇金淋巴瘤化疗期间发展的Vogt-Koyanagi-Harada疾病:一个病例报告
Mutsumi Koyama1, Euido Nishijima1, Takaya Honda2
1Department of Ophthalmology, The Jikei University School of Medicine, 3-25-8, Nishi-shinbashi, Minato-ku, 105-8561, Tokyo, Japan.
BMC ophthalmology
|March 14, 2024
概括
沃格特-科亚纳吉-哈拉达病 (VKH) 是一种罕见的眼部疾病,在化疗期间患有霍奇金淋巴瘤的儿童中呈现出卵膜炎和血清性视网膜脱落. 及时高剂量类固醇治疗可以保持患者的视力.
科学领域:
- 眼科医生 眼科 眼科
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 在霍奇金淋巴瘤 (HL) 中,眼部表现不常见.
- 这一案例突出了在HL化疗期间出现的Vogt-Koyanagi-Harada (VKH) 疾病.
研究的目的:
- 在接受霍奇金淋巴瘤化疗的儿童中报告一种罕见的VKH疾病病例.
- 在癌症治疗期间强调早期诊断和眼部并发症的及时治疗的重要性.
主要方法:
- 一名患有IIB期霍奇金淋巴瘤的7岁男孩接受了化疗 (OEPA和COPDAC方案).
- 脑膜炎和血清性视网膜脱落的眼部症状是在化疗后出现的.
- 诊断不完整的VKH疾病是基于眼睛的发现,CSF分析和HLA-DR4阳性.
- 治疗涉及高剂量静脉注射普雷尼索隆.
主要成果:
- 静脉注射的普雷尼索隆改善了视力敏度从20/500到20/20 (右眼) 和20/63到20/25 (左眼).
- 血清性视网膜脱落随着治疗而消失.
- 白风的发展证实了VKH疾病的完整诊断.
结论:
- 在HLA-DR4阳性儿童的霍奇金淋巴瘤化疗期间发生了VKH疾病的发病.
- 抗癌药物没有涉及引起脑膜炎.
- 早期VKH诊断和高剂量普雷尼松治疗在HL化疗期间保持了良好的视觉功能.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
288
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
288
Cytotoxic T Cells-mediated Immune Response
907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


